Cerebrovascular Diseases

Original Paper

Effect of Cilostazol on Cerebral Vasospasm and Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Trial

Matsuda N.a · Naraoka M.a · Ohkuma H.a · Shimamura N.a · Ito K.a · Asano K.a · Hasegawa S.b · Takemura A.c

Author affiliations

Department of Neurosurgery aHirosaki University, bKuroishi General Hospital, and cAomori City Hospital, Aomori, Japan

Keywords: Subarachnoid hemorrhageCerebral vasospasmAntiplatelet agentsCerebral aneurysmDelayed neuronal damage caused by spasmRandomized controlled trial

Related Articles for ""
Cerebrovasc Dis 2016;42:97-105
https://doi.org/10.1159/000445509

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 18, 2016
Accepted: March 13, 2016
Published online: April 13, 2016
Issue release date: June 2016

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 5

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Abstract

Background: Several clinical studies have indicated the efficacy of cilostazol, a selective inhibitor of phosphodiesterase 3, in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). They were not double-blinded trial resulting in disunited results on assessment of end points among the studies. The randomized, double-blind, placebo-controlled study was performed to assess the effectiveness of cilostazol on cerebral vasospasm. Methods: Patients with aneurysmal SAH admitted within 24 h after the ictus who met the following criteria were enrolled in this study: SAH on CT scan was diffuse thick, diffuse thin, or local thick, Hunt and Hess score was less than 4, administration of cilostazol or placebo could be started within 48 h of SAH. Patients were randomly allocated to placebo or cilostazol after repair of a ruptured saccular aneurysm by aneurysmal neck clipping or endovascular coiling, and the administration of cilostazol or placebo was continued up to 14 days after initiation of treatment. The primary end point was the occurrence of symptomatic vasospasm (sVS), and secondary end points were angiographic vasospasm (aVS) evaluated on digital subtraction angiography, vasospasm-related new cerebral infarction evaluated on CT scan or MRI, and clinical outcome at 3 months of SAH as assessed by Glasgow Outcome Scale, in which poor outcome was defined as severe disability, vegetative state, and death. All end points were evaluated with blinded assessment. Results: One hundred forty eight patients were randomly allocated to the cilostazol group (n = 74) or the control group (n = 74). The occurrence of sVS was significantly lower in the cilostazol group than in the control group (10.8 vs. 24.3%, p = 0.031), and multiple logistic analysis showed that cilostazol use was an independent factor reducing sVS (OR 0.293, 95% CI 0.099-0.568, p = 0.027). The incidence of aVS and vasospasm-related cerebral infarction were not significantly different between the groups. Poor outcome was significantly lower in the cilostazol group than in the control group (5.4 vs. 17.6%, p = 0.011), and multiple logistic analyses demonstrated that cilostazol use was an independent factor that reduced the incidence of poor outcome (OR 0.221, 95% CI 0.054-0.903, p = 0.035). Severe adverse events due to cilostazol administration did not occur during the study period. Conclusions: Cilostazol administration is effective in preventing sVS and improving outcomes without severe adverse events. A larger-scale study including more cases was necessary to confirm this efficacy of cilostazol.

© 2016 S. Karger AG, Basel



Related Articles:

References

  1. Kuramatsu JB, Kollmar R, Gerner ST, Madžar D, Pisarčíková A, Staykov D, Kloska SP, Doerfler A, Eyüpoglu IY, Schwab S, Huttner HB: Is hypothermia helpful in severe subarachnoid hemorrhage? An exploratory study on macro vascular spasm, delayed cerebral infarction and functional outcome after prolonged hypothermia. Cerebrovasc Dis 2015;40:228-235.
  2. Uozumi Y, Sakowitz O, Orakcioglu B, Santos E, Kentar M, Haux D, Unterberg A: Decompressive craniectomy in patients with aneurysmal subarachnoid hemorrhage: a single-center matched-pair analysis. Cerebrovasc Dis 2014;37:109-115.
  3. Tso MK, Macdonald RL: Subarachnoid hemorrhage: a review of experimental studies on the microcirculation and the neurovascular unit. Transl Stroke Res 2014;5:174-189.
  4. Fujii M, Yan J, Rolland WB, Soejima Y, Caner B, Zhang JH: Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res 2013;4:432-446.
  5. Dreier JP: The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 2011;17:439-447.
  6. Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL: Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2011;31:1443-1451.
  7. Yamaguchi-Okada M, Nishizawa S, Mizutani A, Namba H: Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. Cerebrovasc Dis 2009;28:135-142.
  8. Nishino A, Umegaki M, Fujinaka T, Yoshimine T: Cilostazol attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. Neurol Res 2010;32:873-878.
  9. Ito H, Fukunaga M, Suzuki H, Miyakoda G, Ishikawa M, Yabuuchi Y, Taki W: Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis 2008;32:157-161.
  10. Uchiyama S, Shinohara Y, Katayama Y, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C: Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. Cerebrovasc Dis 2014;37:296-303.
  11. Uchiyama S, Sakai N, Toi S, Ezura M, Okada Y, Takagi M, Nagai Y, Matsubara Y, Minematsu K, Suzuki N, Tanahashi N, Taki W, Nagata I, Matsumoto M; CATHARSIS Study Group: Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS). Cerebrovasc Dis Extra 2015;15:1-13.
  12. Ota H, Eto M, Kano MR, Ogawa S, Iijima K, Akishita M, Ouchi Y: Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:1634-1639.
  13. Ba XH, Cai LP, Han W: Effect of cilostazol pretreatment on the PARP/AIF-mediated apoptotic pathway in rat cerebral ischemia-reperfusion models. Exp Ther Med 2014;7:1209-1214.
  14. Ito H, Hashimoto A, Matsumoto Y, Yao H, Miyakoda G: Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. J Cereb Blood Flow Metab 2010;30:343-351.
  15. Suzuki S, Sayama T, Nakamura T, Nishimura H, Ohta M, Inoue T, Mannoji H, Takeshita I: Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. Cerebrovasc Dis 2011;32:89-93.
  16. Senbokuya N, Kinouchi H, Kanemaru K, Ohashi Y, Fukamachi A, Yagi S, Shimizu T, Furuya K, Uchida M, Takeuchi N, Nakano S, Koizumi H, Kobayashi C, Fukasawa I, Takahashi T, Kuroda K, Nishiyama Y, Yoshioka H, Horikoshi T: Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. J Neurosurg 2013;118:121-130.
  17. Yoshimoto T, Shirasaka T, Fujimoto S, Yoshidumi T, Yamauchi T, Tokuda K, Kaneko S, Kashiwaba T: Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 2009;49:235-240; discussion 240-241.
  18. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, et al: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76:571-577.
  19. Ohkuma H, Manabe H, Tanaka M, Suzuki S: Impact of cerebral microcirculatory changes on cerebral blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2000;31:1621-1627.
  20. Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N, Connolly ES, Mayer SA: Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke 2009;40:1963-1968.
  21. Frontera JA, Claassen J, Schmidt JM, Wartenberg KE, Temes R, Connolly ES Jr, MacDonald RL, Mayer SA: Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery 2006;59:21-27; discussion 21-27.
  22. Macdonald RL, Rosengart A, Huo D, Karrison T: Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg 2003;99:644-652.
  23. Lanzino G, Kassell NF, Germanson TP, Kongable GL, Truskowski LL, Torner JC, Jane JA: Age and outcome after aneurysmal subarachnoid hemorrhage: why do older patients fare worse? J Neurosurg 1996;85:410-418.
  24. Nakagawa T, Suga S, Mayanagi K, Akaji K, Inamasu J, Kawase T; Keio SAH Cooperative Study Group: Predicting the overall management outcome in patients with a subarachnoid hemorrhage accompanied by a massive intracerebral or full-packed intraventricular hemorrhage: a 15-year retrospective study. Surg Neurol 2005;63:329-334; discussion 334-335.
  25. Shimoda M, Oda S, Mamata Y, Tsugane R, Sato O: Surgical indications in patients with an intracerebral hemorrhage due to ruptured middle cerebral artery aneurysm. J Neurosurg 1997;87:170-175.
  26. Niu PP, Yang G, Xing YQ, Guo ZN, Yang Y: Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurol Sci 2014;336:146-151.
  27. Hashimoto A, Miyakoda G, Hirose Y, Mori T: Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006;189:350-357.
  28. Hashimoto A, Tanaka M, Takeda S, Ito H, Nagano K: Cilostazol Induces PGI2 production via activation of the downstream Epac-1/Rap1 signaling cascade to increase intracellular calcium by PLCε and to activate p44/42 MAPK in human aortic endothelial cells. PLoS One 2015;10:e0132835.
  29. Vergouwen MD, Ilodigwe D, Macdonald RL: Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke 2011;42:924-929.
  30. Brown RJ, Kumar A, Dhar R, Sampson TR, Diringer MN: The relationship between delayed infarcts and angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2013;72:702-707; discussion 707-708.
  31. Ibrahim GM, Weidauer S, Vatter H, Raabe A, Macdonald RL: Attributing hypodensities on CT to angiographic vasospasm is not sensitive and unreliable. Stroke 2012;43:109-112.
  32. Sabri M, Ai J, Lakovic K, D'abbondanza J, Ilodigwe D, Macdonald RL: Mechanisms of microthrombi formation after experimental subarachnoid hemorrhage. Neuroscience 2012;224:26-37.
  33. Friedrich B, Müller F, Feiler S, Schöller K, Plesnila N: Experimental subarachnoid hemorrhage causes early and long-lasting microarterial constriction and microthrombosis: an in-vivo microscopy study. J Cereb Blood Flow Metab 2012;32:447-455.
  34. Pisapia JM, Xu X, Kelly J, Yeung J, Carrion G, Tong H, Meghan S, El-Falaky OM, Grady MS, Smith DH, Zaitsev S, Muzykantov VR, Stiefel MF, Stein SC: Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan. Exp Neurol 2012;233:357-363.
  35. Suzuki S, Kimura M, Souma M, Ohkima H, Shimizu T, Iwabuchi T: Cerebral microthrombosis in symptomatic cerebral vasospasm - a quantitative histological study in autopsy cases. Neurol Med Chir (Tokyo) 1990;30:309-316.
  36. Stein SC, Browne KD, Chen XH, Smith DH, Graham DI: Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery 2006;59:781-787; discussion 787-788.
  37. Hop JW, Rinkel GJ, Algra A, Berkelbach van der Sprenkel JW, van Gijn J: Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage. Neurology 2000;54:872-878.
  38. Shaw MD, Foy PM, Conway M, Pickard JD, Maloney P, Spillane JA, Chadwick DW: Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage. J Neurosurg 1985;63:699-703.
  39. Suzuki S, Sano K, Handa H, Asano T, Tamura A, Yonekawa Y, Ono H, Tachibana N, Hanaoka K: Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol Res 1989;11:79-88.
  40. Dorhout Mees SM, Rinkel GJ, Hop JW, Algra A, van Gijn J: Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: a systematic review. Stroke 2003;34:2285-2289.
  41. Uhl E, Lehmberg J, Steiger HJ, Messmer K: Intraoperative detection of early microvasospasm in patients with subarachnoid hemorrhage by using orthogonal polarization spectral imaging. Neurosurgery 2003;52:1307-1315; discussion 1315-1317.
  42. Pennings FA, Bouma GJ, Ince C: Direct observation of the human cerebral microcirculation during aneurysm surgery reveals increased arteriolar contractility. Stroke 2004;35:1284-1288.
  43. Ohkuma H, Itoh K, Shibata S, Suzuki S: Morphological changes of intraparenchymal arterioles after experimental subarachnoid hemorrhage in dogs. Neurosurgery 1997;41:230-235; discussion 235-236.
  44. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, Yamawaki T, Itoh N, Obara K, Muramatsu K: Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989;20:668-673.
  45. Han SW, Song TJ, Bushnell CD, Lee SS, Kim SH, Lee JH, Kim GS, Kim OJ, Koh IS, Lee JY, Suk SH, Lee SI, Nam HS, Kim WJ, Lee KY, Park JH, Kim JY, Park JH: Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the effect of cilostazol in acute lacunar infarction based on pulsatility index of transcranial Doppler (ECLIPse) study. Cerebrovasc Dis 2014;38:197-203.
  46. Dorhout Mees SM, Rinkel GJ, Hop JW, Algra A, van Gijn J: Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: a systematic review. Stroke 2003;34:2285-2289.
  47. Wostrack M, Sandow N, Vajkoczy P, Schatlo B, Bijlenga P, Schaller K, Kehl V, Harmening K, Ringel F, Ryang YM, Friedrich B, Stoffel M, Meyer B: Subarachnoid haemorrhage WFNS grade V: is maximal treatment worthwhile? Acta Neurochir (Wien) 2013;155:579-586.
  48. Mahaney KB, Todd MM, Torner JC; IHAST Investigators: Variation of patient characteristics, management, and outcome with timing of surgery for aneurysmal subarachnoid hemorrhage. J Neurosurg 2011;114:1045-1053.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 18, 2016
Accepted: March 13, 2016
Published online: April 13, 2016
Issue release date: June 2016

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 5

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2016, Vol.42, No. 1-2

June 2016

Article

Recommend This
TOP